UK markets closed

Bio-Rad Laboratories, Inc. (BIO)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
548.74-0.38 (-0.07%)
At close: 04:03PM EDT
542.32 -6.42 (-1.17%)
After hours: 05:23PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close549.12
Open553.89
Bid399.98 x 1100
Ask547.05 x 800
Day's range542.32 - 556.32
52-week range462.61 - 832.70
Volume69,491
Avg. volume173,056
Market cap16.144B
Beta (5Y monthly)0.95
PE ratio (TTM)N/A
EPS (TTM)-3.39
Earnings date26 Oct 2022 - 31 Oct 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est700.00
  • Business Wire

    Bio-Rad Acquires Curiosity Diagnostics

    HERCULES, Calif., August 03, 2022--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A. (WSE NewConnect: SCP), a Warsaw, Poland, based developer of innovative technology solutions for the medical diagnostic and healthcare markets, for a total consideration of up to $170 mil

  • Zacks

    Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Gross Margin Up

    Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.

  • Zacks

    Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings and Revenue Estimates

    Bio-Rad (BIO) delivered earnings and revenue surprises of 37.40% and 3.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?